Sources
Story Timeline
•Latest version
FDA Nears Approval of exa-cel, a CRISPR-Based Drug for Sickle Cell Disease, Following Safety Study; Decision by December 8
•Original version
FDA Considers Approving CRISPR Gene-Editing Therapy for Sickle Cell Disease by Dec. 8
